

**§ 56.120**

**21 CFR Ch. I (4–1–06 Edition)**

Administration at reasonable times and in a reasonable manner.

(c) The Food and Drug Administration may refuse to consider a clinical investigation in support of an application for a research or marketing permit if the institution or the IRB that reviewed the investigation refuses to allow an inspection under this section.

[46 FR 8975, Jan. 27, 1981, as amended at 56 FR 28029, June 18, 1991; 67 FR 9585, Mar. 4, 2002]

**Subpart E—Administrative Actions  
for Noncompliance**

**§ 56.120 Lesser administrative actions.**

(a) If apparent noncompliance with these regulations in the operation of an IRB is observed by an FDA investigator during an inspection, the inspector will present an oral or written summary of observations to an appropriate representative of the IRB. The Food and Drug Administration may subsequently send a letter describing the noncompliance to the IRB and to the parent institution. The agency will require that the IRB or the parent institution respond to this letter within a time period specified by FDA and describe the corrective actions that will be taken by the IRB, the institution, or both to achieve compliance with these regulations.

(b) On the basis of the IRB's or the institution's response, FDA may schedule a reinspection to confirm the adequacy of corrective actions. In addition, until the IRB or the parent institution takes appropriate corrective action, the agency may:

(1) Withhold approval of new studies subject to the requirements of this part that are conducted at the institution or reviewed by the IRB;

(2) Direct that no new subjects be added to ongoing studies subject to this part;

(3) Terminate ongoing studies subject to this part when doing so would not endanger the subjects; or

(4) When the apparent noncompliance creates a significant threat to the rights and welfare of human subjects, notify relevant State and Federal regulatory agencies and other parties with a direct interest in the agency's action

of the deficiencies in the operation of the IRB.

(c) The parent institution is presumed to be responsible for the operation of an IRB, and the Food and Drug Administration will ordinarily direct any administrative action under this subpart against the institution. However, depending on the evidence of responsibility for deficiencies, determined during the investigation, the Food and Drug Administration may restrict its administrative actions to the IRB or to a component of the parent institution determined to be responsible for formal designation of the IRB.

**§ 56.121 Disqualification of an IRB or an institution.**

(a) Whenever the IRB or the institution has failed to take adequate steps to correct the noncompliance stated in the letter sent by the agency under § 56.120(a), and the Commissioner of Food and Drugs determines that this noncompliance may justify the disqualification of the IRB or of the parent institution, the Commissioner will institute proceedings in accordance with the requirements for a regulatory hearing set forth in part 16.

(b) The Commissioner may disqualify an IRB or the parent institution if the Commissioner determines that:

(1) The IRB has refused or repeatedly failed to comply with any of the regulations set forth in this part, and

(2) The noncompliance adversely affects the rights or welfare of the human subjects in a clinical investigation.

(c) If the Commissioner determines that disqualification is appropriate, the Commissioner will issue an order that explains the basis for the determination and that prescribes any actions to be taken with regard to ongoing clinical research conducted under the review of the IRB. The Food and Drug Administration will send notice of the disqualification to the IRB and the parent institution. Other parties with a direct interest, such as sponsors and clinical investigators, may also be sent a notice of the disqualification. In addition, the agency may elect to publish a notice of its action in the FEDERAL REGISTER.

(d) The Food and Drug Administration will not approve an application for a research permit for a clinical investigation that is to be under the review of a disqualified IRB or that is to be conducted at a disqualified institution, and it may refuse to consider in support of a marketing permit the data from a clinical investigation that was reviewed by a disqualified IRB as conducted at a disqualified institution, unless the IRB or the parent institution is reinstated as provided in § 56.123.

**§ 56.122 Public disclosure of information regarding revocation.**

A determination that the Food and Drug Administration has disqualified an institution and the administrative record regarding that determination are disclosable to the public under part 20.

**§ 56.123 Reinstatement of an IRB or an institution.**

An IRB or an institution may be reinstated if the Commissioner determines, upon an evaluation of a written submission from the IRB or institution that explains the corrective action that the institution or IRB plans to take, that the IRB or institution has provided adequate assurance that it will operate in compliance with the standards set forth in this part. Notification of reinstatement shall be provided to all persons notified under § 56.121(c).

**§ 56.124 Actions alternative or additional to disqualification.**

Disqualification of an IRB or of an institution is independent of, and neither in lieu of nor a precondition to, other proceedings or actions authorized by the act. The Food and Drug Administration may, at any time, through the Department of Justice institute any appropriate judicial proceedings (civil or criminal) and any other appropriate regulatory action, in addition to or in lieu of, and before, at the time of, or after, disqualification. The agency may also refer pertinent matters to another Federal, State, or local government agency for any action that that agency determines to be appropriate.

**PART 58—GOOD LABORATORY PRACTICE FOR NONCLINICAL LABORATORY STUDIES**

**Subpart A—General Provisions**

Sec.

58.1 Scope.

58.3 Definitions.

58.10 Applicability to studies performed under grants and contracts.

58.15 Inspection of a testing facility.

**Subpart B—Organization and Personnel**

58.29 Personnel.

58.31 Testing facility management.

58.33 Study director.

58.35 Quality assurance unit.

**Subpart C—Facilities**

58.41 General.

58.43 Animal care facilities.

58.45 Animal supply facilities.

58.47 Facilities for handling test and control articles.

58.49 Laboratory operation areas.

58.51 Specimen and data storage facilities.

**Subpart D—Equipment**

58.61 Equipment design.

58.63 Maintenance and calibration of equipment.

**Subpart E—Testing Facilities Operation**

58.81 Standard operating procedures.

58.83 Reagents and solutions.

58.90 Animal care.

**Subpart F—Test and Control Articles**

58.105 Test and control article characterization.

58.107 Test and control article handling.

58.113 Mixture of articles with carriers.

**Subpart G—Protocol for and Conduct of a Nonclinical Laboratory Study**

58.120 Protocol.

58.130 Conduct of a nonclinical laboratory study.

**Subparts H–I [Reserved]**

**Subpart J—Records and Reports**

58.185 Reporting of nonclinical laboratory study results.

58.190 Storage and retrieval of records and data.

58.195 Retention of records.